Sophie Payne
Co-founder & CEO
Over a decade of research into how blood vessel cells control their genes, now leading the company from discovery towards partnership.
LinkedIn
Precision genetic medicines to reprogramme dysfunctional cells
We design therapies that act only where they are needed, restoring healthy behaviour in the cells that drive disease and leaving the rest of the body alone.
Talk to us about partneringA more precise way to treat disease
Many of today's medicines work across the whole body. They can be effective, but they often reach healthy tissue too, and the side effects that follow limit how well patients can be treated.
Blue Fern Bio is building a platform that targets therapeutic activity to the specific cells that have gone wrong, then guides those cells back to healthy function.
-
Targeted
Therapeutic activity is switched on only in the cells that need it.
-
Restorative
Rather than blocking a single pathway, we aim to return cells to their healthy state.
-
Learning
AI-guided design means each round of laboratory work informs the next, so better candidates emerge faster.
Our aim is simple: medicines that are more effective because they are more precise.
The people behind Blue Fern Bio
A team bringing together deep expertise in vascular biology, gene regulation, computational science and company building.
Founders
Mark Preston
Co-founder & CTO
Builds AI and bioinformatics systems for biotech, with a background in regulatory science.
LinkedInAdvisers
Francesca Crawford
Strategic Adviser
Serial founder and non-executive director with experience building life science companies.
LinkedIn
Sarah De Val
Scientific Adviser
Professor of Cardiovascular Science and a pioneer in the study of blood vessel gene regulation.
University of OxfordPartner with us
We work with pharmaceutical and biotech partners to bring precise genetic medicines to patients. If you'd like to learn more, we'd be glad to hear from you.